Mike Hollan

WHO designates GLP-1 medications for diabetes as essential, aiming to improve access and affordability for patients worldwide.

Marc Stapley, CEO of Veracyte, reviews upcoming developments in the diagnostic space.

These drugs have quickly become household names due to their popularity as weight loss medications.

The two companies issued statements detailing the number of studies about the vaccines’ impact.

As more companies announce layoffs and other restructuring plans, industry experts are asking what will happen next.

The OSE Immunotherapeutics CEO discusses recent develops with this potentially game-changing space in oncology.

Marc Stapley, CEO of Veracyte, explains how investors are reacting to recent advancements in cancer care.

Noah Nasser discusses how data silos cause complications with researchers.

The company pointed the President to existing published research and pledged to post more to its site.

Marc Stapley, CEO of Veracyte, discusses the importance of ongoing evidence collection.

As the GLP market begins to settle, pharma companies and investors are looking to predict what comes next.

The feature will be available on the company’s platform Nuro.

Noah Nasser discusses how new technologies are changing the data landscape.

Marc Stapley, CEO of Veracyte, discusses new approaches to diagnostics and how its transforming cancer care.

Noah Nasser discusses one of the most critical components of working with RWD.

Michael Grosberg discusses the issues that need to be addressed to bring drug prices down for patients.

Derrick Gastineau discusses the importance of finding the right spaces to ensure patients see accurate information about medications.

Lawyers for Monarez argue that only the president can fire her and that she has no plans to resign.

Derrick Gastineau discusses the importance of patients’ hearing stories from other patients.

The Boehringer Ingelheim leader discusses his leadership style and how it impacts his team’s strategy.

Noah Nasser discusses the importance of keeping data still.

With insured patients less likely to benefit, who actually does benefit from D2C?

Putnam’s CEO discusses advancements in oncology and how companies are working to ensure patients have access to these new treatments.

Derrick Gastineau discusses how the focus on weight loss medications has shifted in recent years.

Michael Grosberg discusses how people with insurance will be impacted by D2C drug sales.

A joint statement lays out the framework for a potential trade agreement.

Staff members published an open letter to the HHS Secretary following a deadly shooting earlier this month.

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives steering innovative scientific and strategic pursuits in R&D, market access, and patient support.

Powering learnings of the dark genome to tackle disease at its source.

Pushing for access wins in quickly evolving market and digital health landscapes.